Chartwell Pharmaceuticals
Lance Kann has a diverse and extensive work experience in the pharmaceutical industry spanning over several decades. Lance has held leadership roles in various companies, including Chartwell Pharmaceuticals, where they served as the Senior Executive Vice President in charge of Corporate Development and Strategy. Prior to that, they were the President of PharmaSupplyPartners, LLC, providing consulting and advisory services to the global pharmaceutical industry. Lance has also been involved in charitable work as a Board Trustee and Advisor for the Brother's Brother Foundation. Earlier in their career, they held executive roles in companies such as Teva Pharmaceuticals, Wyeth Pharmaceuticals, Mylan Pharmaceuticals, Digital Equipment Corporation (USA), and Pfizer.
Lance Kann obtained a Bachelor of Science degree in Biochemistry/Chemistry from Rutgers University. Following this, they pursued a Master of Business Administration (MBA) in Industrial Management at Fairleigh Dickinson University.
This person is not in any offices
Chartwell Pharmaceuticals
CHARTING A COURSE TO WELLNESS Chartwell Pharmaceuticals is a US-based development, manufacturing and commercial organization located in Congers, New York. Our facility produces prescription pharmaceutical products with a commitment to superior quality, compliance, and customer service. Chartwell Pharmaceuticals has a long history as a preferred manufacturing partner for prescription solid dosage products in tablet, capsule, and powders forms. Recent expansion now adds capabilities for suspensions, enemas and liquids manufacturing - including Unit Dose cups. Our rooms are large, our ceilings are high, and facilities are pristine. Our exceptional hands-on leadership team and technical staff bring decades of pharmaceutical industry experience in manufacturing and analytical services for development, scale-up, transferring, changing, launching, and supplying products. Under our own Chartwell labels, our mission is to provide a consistent, timely and quality product supply to our pharmacy customers and their patients. Our current portfolio stands at over 250 Orange Book listed ANDAs and NDAs, with an aggressive asset development and acquisition program in place. Supported by Chartwell Labs, our Formulations and Analytical team, we are quickly continuing to broaden our line through commercial Chartwell-labeled branding. Chartwell Pharmaceuticals is proud to be manufacturing "Made in the USA" products.